The Government of Senegal has committed to achieve UHC by 2022 as a health sector priority. To address poverty and reduce the health system's dependency on out-of-pocket spending, the UHC programme facilitates access to affordable health services for all citizens. Despite limited resources, Senegal has made significant health strides in the past 20 years. A major achievement has been in the reduction of malaria incidence: Senegal now has one of the lowest malaria case incidence rates in West Africa, with a 30 percent reduction in cases between 2015 and 2016,1 due to the implementation of preventive measures recommended by WHO.2 In this connection, the National Malaria Control Strategy and Plan (2016–2020) has adopted a target of reaching 'pre-elimination', while the Master Plan for Integrated NTD Control (2016–2020) aims to eliminate lymphatic filariasis and trachoma by 2020.
ADP collaborated with the Ministry of Health and Social Action (MHSA) to establish a multi-disciplinary coordinating platform to identify and address barriers that limit or prevent the implementation of national disease control programmes. The platform, which involved government policy-makers and technical experts from across national and sub-national agencies, prioritized support for the identification of health research priorities for integration into the new Health Research Strategic Plan for Senegal (2019–2024).
ADP has also engaged with MHSA and the national regulatory body, Direction de la Pharmacie et du Médicament, to identify the interventions and technical support required for the domestication of the AU Model Law on Medical Products Regulation in Senegal.
Another priority area identified by national stakeholders was pharmacovigilance. While the national pharmacovigilance system has been established, reporting of ADRs has been poor, with delays at the central level for causality assessment and data entry. A key challenge is the low technical capacity among health staff. Hence, ADP has provided support to the National Pharmacovigilance Centre for training key personnel on best practices, with the aim of improving management of adverse events. Building on this, ADP will support a formal benchmarking of the national regulatory system and functions to further identify capacity gaps and necessary interventions.
|Country profile a|
|Human Development Index ranking||164|
|Population total (millions)||16|
|Gross national income per capita (USD)||2,384|
|Working poor at PPP $3.10 a day (% of total employment)||63|
|Public health expenditure (% of GDP)||4|
|Life expectancy at birth (years)||68|
|<5 mortality rate (per 1000 live births)||34|
|TB epidemiology b|
|TB incidence (per 100,000)||122|
|Deaths due to TB (per 100,000)||20|
|TB treatment coverage (%)||68|
|MDR-TB incidence (per 100,000)||2|
|Malaria epidemiology c|
|Cases of malaria (per 100,000)||47|
|Deaths due to malaria (per 100,000)||25|
|Children aged <5 years with fever who received treatment with any antimalarial (%) (2013)||6|
|NTDs epidemiology d|
|Population at risk of LF / coverage of PC (2013)||8,533,698 / 71%|
|Population at risk of OCH / coverage of PC||915,362 / 69%|
|SAC at risk of SCH / coverage of PC||3,278,785 / 19%|
|SAC at risk of STH / coverage of PC||6,421,532 / 63%|
All data from 2017 unless stated. PC: preventive chemotherapy; STH: soil-transmitted helminths; LF: lymphatic filariasis; SCH: schistosomiasis; OCH: onchocerciasis.